CPXX and GERN

[sargasso]

It seems to me the recent spectacular price action in CPXX is very encouraging for GERN shareholders. Although admittedly not exactly comparable it appears to me that GERN has developed a far superior drug. It is also interesting to note that “the blood cancer market is already valued at over $24 billion per year, and that's for a cohort of treatments that rarely produce durable responses.” http://www.fool.com/investing/general/2 ... trf0000001

[Fishermangents]

Parts of the Fool text seems familiar. Did they recycle on old article?

CPXX: we should not forget that high risk AML is maybe even more agressive and difficult to treat than high risk MF although both are fatal for many. I am really looking forward to the AML trial, certainly after the promising data from the AACR presentation (abstract 2731).

[Fishermangents]

Btw Sargasso: I agree that the CR's in the high risk Mayo MF patients are a probably a deeper kind of response than the high risk AML patients who benefited from Vyxeos. However, it is difficult to compare.